Propeller Health said today it inked a strategic partnership deal with Express Scripts (NSDQ:ESRX) to provide Propeller’s digital solutions to Express Script members. Through the deal, St. Louis-based Express Script members will be able to use inhaler sensors and connected mobile applications to manage their asthma or chronic obstructive pulmonary disease. The companies touted it as the largest […]
MediWound raises $25m
MediWound (NSDQ:MDWD) today announced a $25.2 million offering to support research and development of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. In the offering, the Israel-based company floated approximately 5 million shares, including 637,664 shares through an underwriter’s option, according to an SEC filing. Cowen & Company and Wells Fargo […]
BioCorRx locks in Jan 2017 pre-IND FDA meeting for naltrexone implant
BioCorRx (OTC:BICX) said late last week it scheduled a pre-investigational new drug meeting with the FDA for its BICX102 naltrexone implant for next January as the company works on an IND application for the implant. The Anaheim, Calif.-based company said that its scheduled pre-IND meeting will not preclude it from submitting its IND application before that date. […]
Revive Therapeutics inks R&D deal with Sanyal for liver disease treatments
Revive Therapeutics (OTC:RVVTF) said today it inked a collaborative research deal with Sanyal Biotechnology looking to explore the use of cannabinoids as potential treatments for liver diseases. The collaborative deal will initially focus on the use of cannabidiol on a novel autoimmune hepatitis model, using the Diamond model which was designed and developed by Sanyal Biotechnologyspecifically […]
Seattle Genetics wins FDA Breakthrough Therapy Designation for Hodgkin lymphoma treatment
Seattle Genetics (NSDQ:SGEN) said today that the FDA granted Breakthrough Therapy Designation to its antibody-drug conjugate Adcetris in combination with chemotherapy for treating patients with advanced classical Hodgkin lymphoma. The approval was based on positive top line results from the company’s phase 3 Echelon-1 clinical trial, which were announced in June. The Bothell, Wash.-based company said […]
J&J’s Janssen wins $45m BARDA contract for Ebola vaccine dev
Johnson & Johnson (NYSE:JNJ) said today that its Janssen Pharmaceutical subsidiary Janssen Vaccines & Prevention B.V received a $44.7 million award and collaborative partnership from the US Biomedical Advanced Research and Development Authority to support its development of an investigational Ebola vaccine regimen. The deal comes with an option for BARDA to provide additional funding over 5 […]
Abbott’s $5B acquisition of Alere set to close tomorrow
Abbott (NYSE:ABT) said today it is looking to close its $5 billion acquisition of Alere (NYSE:ALR) tomorrow, saying it has received all regulatory clearances necessary. The Abbott Park, Ill.-based company said the acquisition will establish it as a “global leader in point of care testing,” which it sees as the fastest growing segment of the $50 billion in vitro […]
US DHS warns of vulnerabilities in Smiths Medical Medfusion 4000 infusion pump
The US Dept. of Homeland Security’s Industrial Control Systems Cyber Emergency Response Team has released a warning over issues with Smiths Medical’s Medfusion 4000 wireless syringe infusion pump after discovering 8 cybersecurity vulnerabilities in the device. The notice is for versions 1.1, 1.5 and 1.6 Medfusion 4000 wireless syringe infusion pumps, according to the DHS […]
Report: Abbott still looking to pull Xience DES from Indian market
Abbott (NYSE:ABT) is still looking to pull its Xience Alpine drug-eluting stent from the Indian marketplace after the country’s regulatory body set significant price caps on stents earlier this year, according to an Indian Economic Times report. The company reportedly approached India’s National Pharmaceutical Pricing Authority looking to withdraw the Xience stent yet again due to caps, along […]
Reva Medical pursues direct-sales after Boston Scientific distro negotiation deal lapses
Reva Medical (ASX:RVA) said today it will take up direct marketing of its peripheral and vascular scaffolds after Boston Scientific‘s (NYSE:BSX) right to negotiate for exclusive distribution of the products expired. San Diego, Calif.-based Reva said that Boston Scientific had gained the right to negotiate for exclusive distribution rights under a 2007 agreement which would have positioned […]
